Re: Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
Dear Prof. Elisabetta Patorno et al:
Taking into account that:
First, Canaglifozin is also a glycosuric diuretic drug, so increasing blood viscosity (1).
Second, Canaglifozin has been associated with increased lower limb amputations in previous randomised clinical trial (2).
In this large retrospective cohort, would it possible to inform us the incidence of amputations with the use of Canaglifozin compared to the other anti-diabetic drugs?
1. Poredos P, Zizek B. Plasma viscosity increase with progression of peripheral arterial atherosclerotic disease. Angiology 1996;47:253-259.
2. Bruce Neal, M.B., Ch.B., Ph.D., Vlado Perkovic, M.B., B.S., Ph.D., Kenneth W. Mahaffey, M.D., Dick de Zeeuw, M.D., Ph.D., Greg Fulcher, M.D., Ngozi Erondu, M.D., Ph.D., Wayne Shaw, D.S.L., Gordon Law, Ph.D., Mehul Desai, M.D., and David R. Matthews, .Phil., B.M., B.Ch. for the CANVAS Program Collaborative Group. N Engl J Med 2017; 377:644-657
Competing interests: No competing interests